56
Participants
Start Date
July 31, 2010
Primary Completion Date
January 31, 2015
Study Completion Date
November 16, 2017
Ad5.hAC6
Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10\^9 vp to 10\^12 vp in 5 dose groups
Sucrose (3%)
University of Wisconsin-Madison, Madison
Minneapolis Heart Institute Foundation, Minneapolis
Northwestern University Feinberg School of Medicine, Chicago
University of Utah Health Care, Utah, Salt Lake City
University of California, San Diego, San Diego
VA San Diego Healthcare System, San Diego
Fletcher Allen Health Care, Burlington
Collaborators (1)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Renova Therapeutics
INDUSTRY
Hammond, H. Kirk, M.D.
INDIV